Zymeworks, Inc. (ZYME)
26.87
+0.01
(+0.04%)
USD |
NASDAQ |
Nov 20, 12:36
Zymeworks Cash from Investing (Quarterly) : -386.22M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -386.22M |
| June 30, 2026 | 16.67M |
| March 31, 2026 | 69.96M |
| December 31, 2025 | 5.097M |
| September 30, 2025 | 0.3261M |
| June 30, 2025 | 9.114M |
| March 31, 2025 | 12.18M |
| December 31, 2024 | -6.886M |
| September 30, 2024 | 71.89M |
| June 30, 2024 | -19.78M |
| March 31, 2024 | -7.316M |
| December 31, 2023 | 1.404M |
| September 30, 2023 | -7.183M |
| June 30, 2023 | -61.38M |
| March 31, 2023 | -138.22M |
| December 31, 2022 | -20.42M |
| September 30, 2022 | -29.87M |
| June 30, 2022 | -21.92M |
| March 31, 2022 | 20.57M |
| December 31, 2021 | -1.992M |
| Date | Value |
|---|---|
| September 30, 2021 | 40.10M |
| June 30, 2021 | 28.86M |
| March 31, 2021 | 76.85M |
| December 31, 2020 | 43.30M |
| September 30, 2020 | 34.60M |
| June 30, 2020 | 82.16M |
| March 31, 2020 | -204.77M |
| December 31, 2019 | -88.80M |
| September 30, 2019 | -22.03M |
| June 30, 2019 | 63.10M |
| March 31, 2019 | 22.00M |
| December 31, 2018 | -35.12M |
| September 30, 2018 | -12.78M |
| June 30, 2018 | -71.66M |
| March 31, 2018 | 12.54M |
| December 31, 2017 | -15.49M |
| September 30, 2017 | -2.190M |
| June 30, 2017 | -20.45M |
| March 31, 2017 | 6.589M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie, Inc. | -10.22B |
| Faeth Therapeutics, Inc. | 0.175M |
| ACADIA Pharmaceuticals, Inc. | -86.15M |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Anika Therapeutics, Inc. | -1.756M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -23.34M |
| Cash from Financing (Quarterly) | 330.62M |
| Free Cash Flow | -111.61M |
| Free Cash Flow Per Share (Quarterly) | -0.307 |
| Free Cash Flow to Equity (Quarterly) | -405.05M |
| Free Cash Flow to Firm (Quarterly) | -16.71M |
| Free Cash Flow Yield | -5.79% |